BA.3.2 — nicknamed "Cicada" — hid inside a single immunocompromised host for roughly two years, accumulated 70+ spike protein mutations, then resurfaced globally. It now circulates in 23 countries and 25 US states as of February 2026. WHO rates its public health risk as "low additional" compared to other Omicron strains. Symptoms mirror previous COVID variants. Current vaccines still protect against severe disease. One unusual finding: this variant infects children more than adults — a reversal of COVID's historical pattern. (Sources: WHO, CDC, Gavi VaccinesWork, CNN — April 2026)
A new COVID-19 variant called BA.3.2 — "Cicada" — just reappeared after disappearing for two years. Scientists confirmed it spread to at least 23 countries and 25 American states as of February 2026. It carries more spike protein mutations than any recent Omicron strain. And it does something no previous COVID variant has done clearly: it targets children more than adults. Here is everything confirmed so far — symptoms, vaccine status, and what it means for India.
What Is the Cicada COVID Variant?
BA.3.2 belongs to the Omicron family. When Omicron first swept the world in late 2021, it split into five main branches. Four of them drove massive global waves. The fifth — BA.3 — went quiet almost immediately after detection in 2022. Scientists now believe the virus spent roughly two years evolving inside a single chronically infected, immunocompromised person. That prolonged infection gave the virus time to mutate heavily under immune pressure — a process researchers call a saltation event: a sudden evolutionary leap rather than gradual change.
South African surveillance teams first detected BA.3.2 in November 2024. Genetic analysis suggests it started mutating as far back as late 2023. The name "Cicada" refers to the insect's well-known pattern — years underground, then a sudden, loud emergence.
As of February 2026, BA.3.2 spread to at least 23 countries. The CDC confirmed detections in at least 25 US states. Europe leads in case share — Cicada accounts for approximately 30 percent of COVID infections across the continent, with Germany, Denmark, and the Netherlands reporting the highest counts. Wastewater surveillance from Stanford's WastewaterSCAN program detected BA.3.2 in 11 percent of US national sewage samples during the week ending March 21, 2026.
How Many Mutations Does It Carry?
BA.3.2 carries more than 70 mutations compared to the original Wuhan strain, and more than 50 mutations in the spike protein alone relative to BA.3, according to WHO's December 2025 risk evaluation. This makes it one of the most heavily mutated Omicron variants scientists have tracked.
The spike protein matters because the immune system targets it first. The more the spike protein changes, the harder antibodies — whether from vaccines or prior infection — work to recognise and neutralise the virus. Many of BA.3.2's mutations concentrate specifically in this region, raising reasonable concern about immune evasion.
Some studies suggest BA.3.2's immune-escape ability comes with a built-in trade-off. While it evades antibodies more effectively than dominant strains, it may infect cells less efficiently — which could limit how fast it spreads. A study by Krammer et al. found that antibodies from the KP.2-targeted 2024–25 vaccines still neutralised BA.3.2 effectively, which researchers say may explain why this heavily mutated variant has not yet driven a major global wave.
Symptoms — What to Watch For
BA.3.2 does not produce a distinct symptom set. Doctors at Johns Hopkins confirm no single symptom separates Cicada from the flu or common cold. The CDC lists the following as common COVID-19 symptoms in 2026, all of which apply to BA.3.2:
- Sore throat
- Fever or chills
- Headache
- Cough
- Body aches
- Runny nose
Symptoms typically resolve on their own with supportive care. Testing remains the only reliable way to confirm diagnosis — at-home rapid tests work. The important update for treatment: existing COVID antivirals, including Paxlovid, remain effective against BA.3.2. The variant's mutations focus on immune evasion, not on resisting antiviral drugs.
WHO's December 2025 risk assessment confirms: BA.3.2 shows no increased severity, no rise in hospitalisations, and no surge in deaths compared to other circulating Omicron descendants. The overall evidence suggests BA.3.2 poses low additional public health risk compared with other Omicron lineages in circulation.
Why Is It Hitting Kids More Than Adults?
This is the detail that sets Cicada apart from every COVID variant before it. Scientists say BA.3.2 infects children at higher rates than adults — a clear reversal of the pattern COVID maintained throughout most of the pandemic, where older adults consistently faced the highest risk.
Researchers do not fully understand why yet. One leading theory: adults carry broader immune memory from repeated Omicron exposures and multiple vaccine updates, while children with less prior COVID exposure respond differently to the spike protein mutations BA.3.2 carries.
"Cicada" seemed to be the right fit because it has done the same kind of disappearing routine. Scientists think that for two years, BA.3 infected a single person who didn't have enough immune function to completely fight it off. In some cases, after a long-term infection, the virus re-emerges and begins to circulate again — as seems to have happened here.
CNN's April 2, 2026 report highlights that scientists treat this age inversion as scientifically significant — not because Cicada causes more severe disease in children, but because it signals something new about how this virus continues to evolve. For now, confirmed severity data in children remains low. But pediatric respiratory symptoms in 2026 deserve a COVID test, not just a flu assumption.
Do Current Vaccines Still Work?
Yes — with important context. The 2025–2026 COVID vaccines target the JN.1 lineage. Lab studies show these vaccines produce fewer neutralising antibodies against BA.3.2 compared to dominant strains. A recent Lancet study confirmed the current COVID-19 vaccine performs less effectively against BA.3.2 than against currently dominant strains, though it does provide meaningful protection.
WHO and the CDC both maintain: existing vaccines continue to protect against severe disease, hospitalisations, and death. Dr. William Schaffner of Vanderbilt University states the core point clearly — vaccines work best at keeping people out of hospital, not at preventing mild infection. That remains true for Cicada.
| Vaccine Status | Protection Against BA.3.2 |
|---|---|
| 2025–26 vaccine (JN.1-targeted) | Reduced but present — lab data shows lower neutralisation |
| Severe disease / hospitalisation | Still effective — WHO and CDC confirm |
| Mild infection prevention | Limited — same limitation applies to all recent COVID vaccines |
| Antiviral treatments (Paxlovid etc.) | Fully effective — mutations do not affect antiviral targets |
Sources: CDC, WHO, Lancet, Vanderbilt University — April 2026
Health officials typically update vaccine formulations during summer. A Cicada-adjusted vaccine update could come later in 2026 if the variant gains more ground globally.
Should India Be Worried?
No confirmed Cicada wave has emerged in India as of April 2026. The variant circulates primarily across Europe and the US, with detections confirmed in 23 countries. India's COVID surveillance operates less systematically today than it did during the pandemic's peak, which means the variant could circulate at low levels without immediate detection.
India's multi-generational household structure adds one specific risk factor: school-going children who pick up BA.3.2 can easily expose elderly grandparents in the same home — the exact combination that matters for severity risk, even if the variant causes mild disease overall.
- Test before assuming cold or flu — especially for children with respiratory symptoms in 2026
- Stay current on vaccines — get the latest COVID booster if your last shot was over 12 months ago
- High-risk individuals consult their doctor — seniors, immunocompromised patients, and those with chronic illness face the highest risk from any new variant
- Follow ICMR and WHO updates — official guidance will reflect India-specific data when it becomes available
Frequently Asked Questions
BA.3.2 is a heavily mutated descendant of the Omicron BA.3 subvariant that first appeared in late 2021 but went dormant almost immediately. Scientists believe it evolved silently inside a single chronically infected person for roughly two years before re-emerging. South African surveillance teams detected it in November 2024. It carries more than 70 mutations compared to the original Wuhan strain, making it one of the most mutated Omicron variants ever recorded. The nickname "Cicada" refers to the insect's pattern of years underground followed by sudden emergence.
BA.3.2 symptoms match those of all recent COVID variants and closely resemble the flu and common cold. The CDC lists sore throat, fever or chills, headache, cough, body aches, and runny nose as the primary symptoms in 2026. No distinct symptom separates Cicada from other respiratory illnesses. Testing remains the only reliable diagnostic method. Symptoms typically resolve on their own. Existing COVID antivirals like Paxlovid remain effective against this variant.
Scientists do not yet have a definitive answer. The leading theory: adults carry stronger and broader immune memory from multiple Omicron infections and vaccine updates, while children with less prior COVID exposure may respond differently to BA.3.2's heavily mutated spike protein. This age inversion — where children face higher infection rates than older adults — marks a significant departure from COVID's historical pattern. Importantly, the variant does not cause more severe disease in children. Pediatric severity data still remains low.
Yes — particularly against severe disease. Lab studies show the current 2025–26 JN.1-targeted vaccines produce fewer neutralising antibodies against BA.3.2 than against dominant strains, confirming partial immune evasion. However, WHO and the CDC both state the vaccines continue to protect against severe illness, hospitalisation, and death. A Lancet study confirmed reduced but present protection. Vaccine formulations typically update during summer, so a Cicada-adjusted version may arrive later in 2026.
No confirmed Cicada wave has emerged in India as of April 2026. The variant currently circulates primarily across Europe and the US, with detections in 23 countries total. India's COVID surveillance system operates less actively than during the pandemic peak, which means low-level circulation could go undetected temporarily. Indian families with school-going children or elderly members should monitor respiratory symptoms closely and test rather than assume seasonal cold or flu.
The Bottom Line
- BA.3.2 hid for two years, mutated more than any recent Omicron variant, and now circulates across 23 countries and 25 US states. WHO classifies it as a Variant Under Monitoring — active surveillance, not emergency status.
- It does not cause more severe disease than previous variants. WHO, CDC, and independent researchers all confirm low additional public health risk. Existing antivirals work. Current vaccines still protect against hospitalisation and death.
- The single most unusual finding: Cicada infects children at higher rates than adults — the first COVID variant to clearly show this pattern. Indian families with young children or elderly grandparents in the same home should test early rather than assume seasonal illness.
For more on how new health developments affect daily life in India, read our Health section on UpdateDecoded.
A new COVID-19 variant called BA.3.2 — “Cicada” — just reappeared after disappearing for two years. Scientists confirmed it spread to at least 23 countries and 25 American states as of February 2026. It carries more spike protein mutations than any recent Omicron strain. And it does something no previous COVID variant has done clearly: it targets children more than adults. Here is everything confirmed so far — symptoms, vaccine status, and what it means for India.
What Is the Cicada COVID Variant?
BA.3.2 belongs to the Omicron family. When Omicron first swept the world in late 2021, it split into five main branches. Four of them drove massive global waves. The fifth — BA.3 — went quiet almost immediately after detection in 2022. Scientists now believe the virus spent roughly two years evolving inside a single chronically infected, immunocompromised person. That prolonged infection gave the virus time to mutate heavily under immune pressure — a process researchers call a saltation event: a sudden evolutionary leap rather than gradual change.
South African surveillance teams first detected BA.3.2 in November 2024. Genetic analysis suggests it started mutating as far back as late 2023. The name “Cicada” refers to the insect’s well-known pattern — years underground, then a sudden, loud emergence.
Where BA.3.2 Stands Right NowAs of February 2026, BA.3.2 spread to at least 23 countries. The CDC confirmed detections in at least 25 US states. Europe leads in case share — Cicada accounts for approximately 30 percent of COVID infections across the continent, with Germany, Denmark, and the Netherlands reporting the highest counts. Wastewater surveillance from Stanford’s WastewaterSCAN program detected BA.3.2 in 11 percent of US national sewage samples during the week ending March 21, 2026.
How Many Mutations Does It Carry?
BA.3.2 carries more than 70 mutations compared to the original Wuhan strain, and more than 50 mutations in the spike protein alone relative to BA.3, according to WHO’s December 2025 risk evaluation. This makes it one of the most heavily mutated Omicron variants scientists have tracked.
The spike protein matters because the immune system targets it first. The more the spike protein changes, the harder antibodies — whether from vaccines or prior infection — work to recognise and neutralise the virus. Many of BA.3.2’s mutations concentrate specifically in this region, raising reasonable concern about immune evasion.
The Immune Trade-OffSome studies suggest BA.3.2’s immune-escape ability comes with a built-in trade-off. While it evades antibodies more effectively than dominant strains, it may infect cells less efficiently — which could limit how fast it spreads. A study by Krammer et al. found that antibodies from the KP.2-targeted 2024–25 vaccines still neutralised BA.3.2 effectively, which researchers say may explain why this heavily mutated variant has not yet driven a major global wave.
Symptoms — What to Watch For
BA.3.2 does not produce a distinct symptom set. Doctors at Johns Hopkins confirm no single symptom separates Cicada from the flu or common cold. The CDC lists the following as common COVID-19 symptoms in 2026, all of which apply to BA.3.2:
- Sore throat
- Fever or chills
- Headache
- Cough
- Body aches
- Runny nose
Symptoms typically resolve on their own with supportive care. Testing remains the only reliable way to confirm diagnosis — at-home rapid tests work. The important update for treatment: existing COVID antivirals, including Paxlovid, remain effective against BA.3.2. The variant’s mutations focus on immune evasion, not on resisting antiviral drugs.
WHO on Disease SeverityWHO’s December 2025 risk assessment confirms: BA.3.2 shows no increased severity, no rise in hospitalisations, and no surge in deaths compared to other circulating Omicron descendants. The overall evidence suggests BA.3.2 poses low additional public health risk compared with other Omicron lineages in circulation.
Why Is It Hitting Kids More Than Adults?
This is the detail that sets Cicada apart from every COVID variant before it. Scientists say BA.3.2 infects children at higher rates than adults — a clear reversal of the pattern COVID maintained throughout most of the pandemic, where older adults consistently faced the highest risk.
Researchers do not fully understand why yet. One leading theory: adults carry broader immune memory from repeated Omicron exposures and multiple vaccine updates, while children with less prior COVID exposure respond differently to the spike protein mutations BA.3.2 carries.
“Cicada” seemed to be the right fit because it has done the same kind of disappearing routine. Scientists think that for two years, BA.3 infected a single person who didn’t have enough immune function to completely fight it off. In some cases, after a long-term infection, the virus re-emerges and begins to circulate again — as seems to have happened here.
CNN’s April 2, 2026 report highlights that scientists treat this age inversion as scientifically significant — not because Cicada causes more severe disease in children, but because it signals something new about how this virus continues to evolve. For now, confirmed severity data in children remains low. But pediatric respiratory symptoms in 2026 deserve a COVID test, not just a flu assumption.
Do Current Vaccines Still Work?
Yes — with important context. The 2025–2026 COVID vaccines target the JN.1 lineage. Lab studies show these vaccines produce fewer neutralising antibodies against BA.3.2 compared to dominant strains. A recent Lancet study confirmed the current COVID-19 vaccine performs less effectively against BA.3.2 than against currently dominant strains, though it does provide meaningful protection.
WHO and the CDC both maintain: existing vaccines continue to protect against severe disease, hospitalisations, and death. Dr. William Schaffner of Vanderbilt University states the core point clearly — vaccines work best at keeping people out of hospital, not at preventing mild infection. That remains true for Cicada.
| Vaccine Status | Protection Against BA.3.2 |
|---|---|
| 2025–26 vaccine (JN.1-targeted) | Reduced but present — lab data shows lower neutralisation |
| Severe disease / hospitalisation | Still effective — WHO and CDC confirm |
| Mild infection prevention | Limited — same limitation applies to all recent COVID vaccines |
| Antiviral treatments (Paxlovid etc.) | Fully effective — mutations do not affect antiviral targets |
Sources: CDC, WHO, Lancet, Vanderbilt University — April 2026
Health officials typically update vaccine formulations during summer. A Cicada-adjusted vaccine update could come later in 2026 if the variant gains more ground globally.
Should India Be Worried?
No confirmed Cicada wave has emerged in India as of April 2026. The variant circulates primarily across Europe and the US, with detections confirmed in 23 countries. India’s COVID surveillance operates less systematically today than it did during the pandemic’s peak, which means the variant could circulate at low levels without immediate detection.
India’s multi-generational household structure adds one specific risk factor: school-going children who pick up BA.3.2 can easily expose elderly grandparents in the same home — the exact combination that matters for severity risk, even if the variant causes mild disease overall.
Practical Steps for Indian Families Right Now
- Test before assuming cold or flu — especially for children with respiratory symptoms in 2026
- Stay current on vaccines — get the latest COVID booster if your last shot was over 12 months ago
- High-risk individuals consult their doctor — seniors, immunocompromised patients, and those with chronic illness face the highest risk from any new variant
- Follow ICMR and WHO updates — official guidance will reflect India-specific data when it becomes available
Frequently Asked Questions
BA.3.2 is a heavily mutated descendant of the Omicron BA.3 subvariant that first appeared in late 2021 but went dormant almost immediately. Scientists believe it evolved silently inside a single chronically infected person for roughly two years before re-emerging. South African surveillance teams detected it in November 2024. It carries more than 70 mutations compared to the original Wuhan strain, making it one of the most mutated Omicron variants ever recorded. The nickname “Cicada” refers to the insect’s pattern of years underground followed by sudden emergence.
BA.3.2 symptoms match those of all recent COVID variants and closely resemble the flu and common cold. The CDC lists sore throat, fever or chills, headache, cough, body aches, and runny nose as the primary symptoms in 2026. No distinct symptom separates Cicada from other respiratory illnesses. Testing remains the only reliable diagnostic method. Symptoms typically resolve on their own. Existing COVID antivirals like Paxlovid remain effective against this variant.
Scientists do not yet have a definitive answer. The leading theory: adults carry stronger and broader immune memory from multiple Omicron infections and vaccine updates, while children with less prior COVID exposure may respond differently to BA.3.2’s heavily mutated spike protein. This age inversion — where children face higher infection rates than older adults — marks a significant departure from COVID’s historical pattern. Importantly, the variant does not cause more severe disease in children. Pediatric severity data still remains low.
Yes — particularly against severe disease. Lab studies show the current 2025–26 JN.1-targeted vaccines produce fewer neutralising antibodies against BA.3.2 than against dominant strains, confirming partial immune evasion. However, WHO and the CDC both state the vaccines continue to protect against severe illness, hospitalisation, and death. A Lancet study confirmed reduced but present protection. Vaccine formulations typically update during summer, so a Cicada-adjusted version may arrive later in 2026.
No confirmed Cicada wave has emerged in India as of April 2026. The variant currently circulates primarily across Europe and the US, with detections in 23 countries total. India’s COVID surveillance system operates less actively than during the pandemic peak, which means low-level circulation could go undetected temporarily. Indian families with school-going children or elderly members should monitor respiratory symptoms closely and test rather than assume seasonal cold or flu.
The Bottom Line
- BA.3.2 hid for two years, mutated more than any recent Omicron variant, and now circulates across 23 countries and 25 US states. WHO classifies it as a Variant Under Monitoring — active surveillance, not emergency status.
- It does not cause more severe disease than previous variants. WHO, CDC, and independent researchers all confirm low additional public health risk. Existing antivirals work. Current vaccines still protect against hospitalisation and death.
- The single most unusual finding: Cicada infects children at higher rates than adults — the first COVID variant to clearly show this pattern. Indian families with young children or elderly grandparents in the same home should test early rather than assume seasonal illness.
For more on how new health developments affect daily life in India, read our Health section on UpdateDecoded.
